27.08.18: New data presented at ESC Congress 2018:

Results of COMMANDER HF and MARINER studies with rivaroxaban published Studies in very sick patient populations reaffirm and further strengthen the safety profile of rivaroxaban / Study results did not show a statistical difference in primary endpoints / COMMANDER HF study evaluated rivaroxaban in patients following an acute decompensation of heart failure and concomitant coronary artery disease / MARINER study evaluated rivaroxaban in acutely medically ill patientsmehr ...
Source: Bayer IR Newsfeed: Events - Category: Pharmaceuticals Source Type: news